CAR-modified marrow infiltrating lymphocytes efficiently target malignant plasma cells with very low antigen density
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.02.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Nicolas Camviel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL), 1011 Lausanne, Switzerland; Ludwig Institute…. Hauptthemen laut MEDLINE: Plasma Cells, Receptors, Chimeric Antigen, Multiple Myeloma, Immunotherapy, Adoptive. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leukemia and Lymphoma Society, Stiftung Krebsforschung Schweiz.
Abstract (Originalsprache)
B cell maturation antigen (BCMA) is the primary target for chimeric antigen receptor (CAR)-T cell therapies and other immunotherapies in multiple myeloma (MM). Frequent relapses and the need for sequential treatments underscore the importance of alternative targets. We previously developed a dual-antigen-specific CAR recognizing both BCMA and transmembrane activator and CAML interactor (TACI). Here, we efficiently expressed this CAR in patient-derived marrow-infiltrating lymphocytes (MILs) to investigate MM cell killing via both endogenous T cell receptor (TCR) specificities and the CAR. While the patients' MIL TCRs did not recognize or kill autologous malignant plasma cells (PCs), the CAR consistently mediated efficient PC killing even at low or undetectable antigen levels by flow cytometry. Quantification of BCMA and TACI molecules on target cells by direct stochastic optical reconstruction microscopy (dSTORM) revealed that both BCMA and TACI were significantly underestimated by flow cytometry. Analysis by dSTORM allowed us to delineate the dual-antigen sensitivity of the CAR, indicating that CAR-MILs were polyfunctional and killed targets at very low antigen densities. Our findings support the further exploration of TACI as target in MM and underline the value of super-resolution microscopy in assessing antigen density thresholds for CAR-T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL), 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research Lausanne, 1011 Lausanne, Switzerland; Swiss Cance…
- Institute of Physics, Ecole Polytechnique Fédérale Lausanne, 1024 Ecublens, Switzerland.
- Department of Oncology UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL), 1011 Lausanne, Switzerland; Service of Hematology and Central Laboratory of Hematology, Departments of Oncology UN…
- Institute of Physics, Ecole Polytechnique Fédérale Lausanne, 1024 Ecublens, Switzerland; Nanoscale Infection Biology Group, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.
- University Hospital Lausanne (CHUV), 1011 Lausanne, Switzerland; University of Lausanne (UNIL), 1011 Lausanne, Switzerland.
Förderung
- Leukemia and Lymphoma Society
- Stiftung Krebsforschung Schweiz
Zitieren
APA
Camviel, N., Gambarotto, D., Andre, V., Stadelmann, R., Sieben, C., Gottardo, R., Manley, S., & Arber, C. (2026). CAR-modified marrow infiltrating lymphocytes efficiently target malignant plasma cells with very low antigen density. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.02.004
Vancouver
Camviel N, Gambarotto D, Andre V, Stadelmann R, Sieben C, Gottardo R, et al. CAR-modified marrow infiltrating lymphocytes efficiently target malignant plasma cells with very low antigen density. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.02.004
BibTeX
@article{Camviel2026,
author = {Camviel, Nicolas and Gambarotto, Davide and Andre, Violaine and Stadelmann, Raphael and Sieben, Christian and Gottardo, Raphael and Manley, Suliana and Arber, Caroline},
title = {CAR-modified marrow infiltrating lymphocytes efficiently target malignant plasma cells with very low antigen density},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.02.004}
}
EUVIMED